| Bioactivity | AChE/BChE/BACE-1-IN-2 (Compound 4o) is an orally active inhibitor of AChE, BChE, and BACE-1 with IC50 values of 0.069, 0.127 and 0.097 μM against hAChE, hBChE and hBACE-1, respectively. AChE/BChE/BACE-1-IN-2 shows considerable PAS-AChE binding capability, excellent brain permeation, potential disassembly of Aβ aggregates, and neuroprotective activity against Aβ-induced stress. AChE/BChE/BACE-1-IN-2 has remarkable antioxidant potential[1]. |
| Target | IC50: 0.069 μM (hAChE), 0.097 μM (hBACE-1), 0.127 μM (hBChE) |
| In Vivo | AChE/BChE/BACE-1-IN-2 (Compound 4o) (0-10 mg/kg; p.o.) ameliorates cognitive dysfunction against the scopolamine-induced amnesia model in the Y-maze test[1]. |
| Name | AChE/BChE/BACE-1-IN-2 |
| CAS | 1877000-20-8 |
| Formula | C18H20F2N2 |
| Molar Mass | 302.36 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Choubey PK, et al. Design, synthesis, and multitargeted profiling of N-benzylpyrrolidine derivatives for the treatment of Alzheimer's disease. Bioorg Med Chem. 2020 Nov 15;28(22):115721. |
AChE/BChE/BACE-1-IN-2
CAS: 1877000-20-8 F: C18H20F2N2 W: 302.36
AChE/BChE/BACE-1-IN-2 (Compound 4o) is an orally active inhibitor of AChE, BChE, and BACE-1 with IC50 values of 0.069, 0
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.